AlzeCure Secures €2.5M EU Grant for Phase IIa Trial of NeuroRestore ACD856 in Alzheimer's Disease

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a Swedish pharmaceutical company specializing in candidate drugs for diseases affecting the nervous system, has received a €2.5 million grant from the European Innovation Council (EIC) to support its planned Phase IIa study of NeuroRestore ACD856 in Alzheimer's patients. This funding will enable the company to advance its clinical trials and bring this much-needed Alzheimer's treatment to patients more quickly.

ACD856, a first-in-class drug candidate for Alzheimer's disease, has shown promising results in preclinical and early clinical studies. The substance has demonstrated good safety and tolerability, enters the brain to a high extent, and activates regions relevant for both cognition and depression. Preclinical studies have also shown that ACD856 strengthens communication between nerve cells, improves cognitive ability, and has neuroprotective, anti-inflammatory, and disease-modifying effects in various models.

The Phase IIa clinical trial will evaluate the efficacy and safety of ACD856 in Alzheimer's patients and explore higher doses of the substance, given its good safety profile. The trial will also assess the drug's potential disease-modifying effects, which could address the underlying pathology of Alzheimer's disease. This is a significant milestone for AlzeCure Pharma, as positive results could validate the drug candidate's potential and strengthen the company's pipeline.

The EIC Accelerator program's recognition of the project through the grant serves as a strong validation of AlzeCure's innovative approach to Alzheimer's treatment. This validation can enhance the company's reputation and attract further investment. The grant can also help AlzeCure meet its financial projections by providing additional funding for the clinical trial without diluting existing shareholders.

ACD856's unique pharmacological mechanism enables multiple indications, including neurodegenerative diseases such as Alzheimer's and Parkinson's disease, as well as depression. This versatility could expand the market and patient population for the drug, further enhancing its commercial potential.

In conclusion, AlzeCure Pharma's receipt of a €2.5 million grant from the European Innovation Council for the Phase IIa study of NeuroRestore ACD856 in Alzheimer's patients is a significant achievement for the company. This funding will support the advancement of the drug candidate's clinical development and bring this much-needed treatment to patients more quickly. The grant also serves as a strong validation of the project and its potential to address the underlying pathology of Alzheimer's disease.